The Chinese drug administration approved the supplementary application of China Meheco Group's (SHA:600056) unit, Hainan General Kangli Pharmaceutical, for flumazenil injection after passing a consistency evaluation, according to a Shanghai Stock Exchange disclosure on Tuesday.
The evaluation tested the drug's quality and efficacy.
The drug is mainly used to reverse the central nervous system sedation caused by benzodiazepines, the pharmaceutical company said.
The company's shares rose less than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments